Cancer Gene Therapy Market to Grow at a Robust CAGR 20.42% by 2031 Innovations in Combination Therapies Drive Future Potential

Skyquest Technology
Cancer Gene Therapy Market Size, Share, Growth Analysis, By Therapy(Gene Induced Immunotherapy, Oncolytic Virotherapy, and Gene Transfer), By Indication(Breast Cancer, Ovarian Cancer, Liver Cancer, Pancreatic Cancer), By End User(Hospitals, Diagnostic centers, Research Institutes, and Others), By Region – Industry Forecast 2024-2031

Cancer Gene Therapy Market size was valued at USD 2.38 billion in 2022 and is poised to grow from USD 2.86 billion in 2023 to USD 12.63 billion by 2031, growing at a CAGR of 20.42% in the forecast period (2024-2031).

The global Cancer Gene Therapy Market is a very promising and gaining huge popularity due to its high success rate in preclinical as well as clinical trials. Also, the existing research and development strategies implemented by the pharmaceutical firms to develop novel drugs is trending in the market.

Combination therapies integrating vaccinations are expected to be more effective than just vaccine alone. Vaccinations for cancer that only developed slight immune response could support as an additional treatment used along with surgery or chemotherapy to remove the present cancer cells. With the continuing clinical trials, gene therapy cancer injections or vaccines could soon reach their full potential. As the early stages of vaccine research are winding up, it is possible that soon there will be cancer treatments that work and include vaccinations in the treatment plan.

Download a detailed overview:

Growing Number of Novel Therapeutic Approaches to Drive the Market

Gene therapy holds can capably use numerous unique genes like any suicidal gene, siRNA gene, anti-angiogenesis, immunotherapeutic gene, gene-directed enzyme prodrug, and oncolytic gene.  Also, the market is witnessing novel therapeutic methods by the developments in gene transfer techniques. This supports the established treatments of cancer that directly modify the DNA. There are extensive studies made by preclinical research for better aiming and tumor-selective expression. However, multiple problems are still present before these techniques can be used on patients.

McKinsey launchesa novel Digital Capability Center for encouraging the production of gene &cell therapies. The new Digital Capability Center will focus on uplifting operational productivity and digital revolutions in bio-pharma production in partnership with NJII.
Sino Biological, Inc., a biotechnology company, and InDevR, Inc., a leader in analytical solutions for vaccine in-process and quality control testing, today announced a new conglomeration to speed up the progress of multiplexed assays for a wider range of vaccine, mRNA therapies, and cell and gene therapy applications.

Request Free Customization of this report:

CGT Catapult, an independent innovation and technology organization, and Cellular Origins, a TTP Company focused on enabling scalable, efficient, and cost-effective manufacture of CGTs, today announced a collaboration to demonstrate universal automation of CGT manufacturing. The cooperation will physically and digitally integrate the current bioprocessing equipment using Cellular Origins’ Constellation robotic platform at the CGT Catapult’s Stevenage (MIC) Manufacturing Innovation Centre.
A group of electrical engineering experts at the University of Wisconsin, in Madison have created a stimulating technique that may increase the body’s receptiveness to specific gene therapies, thereby improving the administration of expensive medical treatments. When liver cells were exposed to short-term electric pulses, as opposed to cells that were not open to pulsed electric fields, the liver cells absorbed over 40 times the amount of gene therapy material. This will increase safety and drive cost effectiveness by reducing the dosage needed.

View report summary and Table of Contents (TOC):

Gene therapy is a fresh medical experiment holding promises for cancer treatment. It can treat cancer in 2 different ways: either by reversing the harmful mutations causing cancer in the first place or by directly attacking the cancer cells. Previous technologies, such as CAR-T are widely utilized for cancer treatment, and the latter, gene replacement is in the research phase owing to complexexpensive nature and genetic makeup. As the technologies improve, it will be adopted expansively, reducing its cost and driving itsaffordability.

Related Reports:

Blockchain Market

Visit Our Website:

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email: Send Email
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States

How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

Stay up to date
Register now to get updates on promotions and coupons

Shopping cart